A simple in vitro PK/PD model system to determine time-kill curves of drugs against Mycobacteria

Tuberculosis

Volumn 89, Issue 5, 2009, Pages 378-385

  Budha, Nageshwar R ^a   Lee, Robin B ^a   Hurdle, Julian G ^a   Lee, Richard E ^a   Meibohm, Bernd ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ISONIAZID;

ANTIBACTERIAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BACTERICIDAL ACTIVITY; DRUG ELIMINATION; DRUG HALF LIFE; IN VITRO STUDY; MATHEMATICAL MODEL; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM BOVIS; MYCOBACTERIUM TUBERCULOSIS; PRIORITY JOURNAL;

ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, BACTERIAL; HUMANS; ISONIAZID; MODELS, BIOLOGICAL; MYCOBACTERIUM BOVIS; TIME FACTORS; TUBERCULOSIS;

EID: 70350569315     PISSN: 14729792     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tube.2009.08.002     Document Type: Article

References (41)

1. Schuck E.L., and Derendorf H. Pharmacokinetic/pharmacodynamic evaluation of anti-infective agents. Expert Rev Anti Infect Ther 3 (2005) 361-373
2. Mueller M., de la Pena A., and Derendorf H. Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: kill curves versus MIC. Antimicrob Agents Chemother 48 (2004) 369-377
3. Katsube T., Yano Y., Yamano Y., Munekage T., Kuroda N., and Takano M. Pharmacokinetic-pharmacodynamic modeling and simulation for bactericidal effect in an in vitro dynamic model. J Pharm Sci 97 (2008) 4108-4117
4. Czock D., and Keller F. Mechanism-based pharmacokinetic-pharmacodynamic modeling of antimicrobial drug effects. J Pharmacokinet Pharmacodyn 34 (2007) 727-751
5. Meibohm B., and Derendorf H. Pharmacokinetic/pharmacodynamic studies in drug product development. J Pharm Sci 91 (2002) 18-31
6. The U.S. Department of Health and Human Services Food and Drug Administration. Developing antimicribial drugs-general considerations for clinical trials. Rockville, MD; 1998.
7. The European Agency for the Evaluation of Medicinal Products (EMEA) - Committee for Proprietary Medicinal Products (CPMP). Points to consider on pharmacokinetics and pharmacodynamics in the development of antibacterial medicinal products. London, UK; 2000.
8. Lowdin E., Odenholt I., Bengtsson S., and Cars O. Pharmacodynamic effects of sub-MICs of benzylpenicillin against Streptococcus pyogenes in a newly developed in vitro kinetic model. Antimicrob Agents Chemother 40 (1996) 2478-2482
9. Nolting A., Dalla Costa T., Rand K.H., and Derendorf H. Pharmacokinetic-pharmacodynamic modeling of the antibiotic effect of piperacillin in vitro. Pharm Res 13 (1996) 91-96
10. Dalla Costa T., Nolting A., Rand K., and Derendorf H. Pharmacokinetic-pharmacodynamic modelling of the in vitro antiinfective effect of piperacillin-tazobactam combinations. Int J Clin Pharmacol Ther 35 (1997) 426-433
11. Lister P.D. The role of pharmacodynamic research in the assessment and development of new antibacterial drugs. Biochem Pharmacol 71 (2006) 1057-1065
12. Grasso S., Meinardi G., de Carneri I., and Tamassia V. New in vitro model to study the effect of antibiotic concentration and rate of elimination on antibacterial activity. Antimicrob Agents Chemother 13 (1978) 570-576
13. Maggiolo F., Taras A., Frontespezi S., Bottari F., Legnani M.C., and Suter F. Bactericidal activity of two different dosage regimens of imipenem in an in-vitro dynamic model. J Antimicrob Chemother 32 (1993) 295-300
14. Murakawa T., Sakamoto H., Hirose T., and Nishida M. New in vitro kinetic model for evaluating bactericidal efficacy of antibiotics. Antimicrob Agents Chemother 18 (1980) 377-381
15. Gumbo T., Louie A., Deziel M.R., Liu W., Parsons L.M., Salfinger M., et al. Concentration-dependent Mycobacterium tuberculosis killing and prevention of resistance by rifampin. Antimicrob Agents Chemother 51 (2007) 3781-3788
16. Gumbo T., Louie A., Deziel M.R., Parsons L.M., Salfinger M., and Drusano G.L. Selection of a moxifloxacin dose that suppresses drug resistance in Mycobacterium tuberculosis, by use of an in vitro pharmacodynamic infection model and mathematical modeling. J Infect Dis 190 (2004) 1642-1651
17. Gumbo T., Louie A., Liu W., Ambrose P.G., Bhavnani S.M., Brown D., et al. Isoniazid's bactericidal activity ceases because of the emergence of resistance, not depletion of Mycobacterium tuberculosis in the log phase of growth. J Infect Dis 195 (2007) 194-201
18. Gumbo T., Louie A., Liu W., Brown D., Ambrose P.G., Bhavnani S.M., et al. Isoniazid bactericidal activity and resistance emergence: integrating pharmacodynamics and pharmacogenomics to predict efficacy in different ethnic populations. Antimicrob Agents Chemother 51 (2007) 2329-2336
19. Peloquin C.A., Jaresko G.S., Yong C.L., Keung A.C., Bulpitt A.E., and Jelliffe R.W. Population pharmacokinetic modeling of isoniazid, rifampin, and pyrazinamide. Antimicrob Agents Chemother 41 (1997) 2670-2679
20. Li Y., Nguyen M.H., Cheng S., Schmidt S., Zhong L., Derendorf H., et al. A pharmacokinetic/pharmacodynamic mathematical model accurately describes the activity of voriconazole against Candida spp. in vitro. Int J Antimicrob Agents 31 (2008) 369-374
21. Middlebrook G. Isoniazid-resistance and catalase activity of tubercle bacilli; a preliminary report. Am Rev Tuberc 69 (1954) 471-472
22. Viveiros M., Portugal I., Bettencourt R., Victor T.C., Jordaan A.M., Leandro C., et al. Isoniazid-induced transient high-level resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother 46 (2002) 2804-2810
23. Colangeli R., Helb D., Sridharan S., Sun J., Varma-Basil M., Hazbon M.H., et al. The Mycobacterium tuberculosis iniA gene is essential for activity of an efflux pump that confers drug tolerance to both isoniazid and ethambutol. Mol Microbiol 55 (2005) 1829-1840
24. Wayne L.G. Mycobacterial speciation. In: Kubica G.P., and Wayne L.G. (Eds). The mycobacteria: a sourcebook (1984), Marcel Dekker, New York 25-66
25. Yano Y., Oguma T., Nagata H., and Sasaki S. Application of logistic growth model to pharmacodynamic analysis of in vitro bactericidal kinetics. J Pharm Sci 87 (1998) 1177-1183
26. Nielsen E.I., Viberg A., Lowdin E., Cars O., Karlsson M.O., and Sandstrom M. Semimechanistic pharmacokinetic/pharmacodynamic model for assessment of activity of antibacterial agents from time-kill curve experiments. Antimicrob Agents Chemother 51 (2007) 128-136
27. Carret G., Flandrois J.P., and Lobry J.R. Biphasic kinetics of bacterial killing by quinolones. J Antimicrob Chemother 27 (1991) 319-327
28. Meagher A.K., Forrest A., Dalhoff A., Stass H., and Schentag J.J. Novel pharmacokinetic-pharmacodynamic model for prediction of outcomes with an extended-release formulation of ciprofloxacin. Antimicrob Agents Chemother 48 (2004) 2061-2068
29. Mouton J.W., Vinks A.A., and Punt N.C. Pharmacokinetic-pharmacodynamic modeling of activity of ceftazidime during continuous and intermittent infusion. Antimicrob Agents Chemother 41 (1997) 733-738
30. Tam V.H., Schilling A.N., Poole K., and Nikolaou M. Mathematical modelling response of Pseudomonas aeruginosa to meropenem. J Antimicrob Chemother 60 (2007) 1302-1309
31. Liu P., Rand K.H., Obermann B., and Derendorf H. Pharmacokinetic-pharmacodynamic modelling of antibacterial activity of cefpodoxime and cefixime in in vitro kinetic models. Int J Antimicrob Agents 25 (2005) 120-129
32. Regoes R.R., Wiuff C., Zappala R.M., Garner K.N., Baquero F., and Levin B.R. Pharmacodynamic functions: a multiparameter approach to the design of antibiotic treatment regimens. Antimicrob Agents Chemother 48 (2004) 3670-3676
33. Tam V.H., Schilling A.N., and Nikolaou M. Modelling time-kill studies to discern the pharmacodynamics of meropenem. J Antimicrob Chemother 55 (2005) 699-706
34. Zhi J., Nightingale C.H., and Quintiliani R. A pharmacodynamic model for the activity of antibiotics against microorganisms under nonsaturable conditions. J Pharm Sci 75 (1986) 1063-1067
35. Jindani A., Aber V.R., Edwards E.A., and Mitchison D.A. The early bactericidal activity of drugs in patients with pulmonary tuberculosis. Am Rev Respir Dis 121 (1980) 939-949
36. Jindani A., Dore C.J., and Mitchison D.A. Bactericidal and sterilizing activities of antituberculosis drugs during the first 14 days. Am J Respir Crit Care Med 167 (2003) 1348-1354
37. Gumbo T., Siyambalapitiyage Dona C.S., Meek C., and Leff R. PharmacokineticsPharmacodynamics of pyrazinamide in a novel in vitro model of Tuberculosis for sterilizing effect: a paradigm for faster assessment of new antituberculosis drugs. Antimicrob Agents Chemother (2009)
38. McClatchy J.K. Mechanism of action of isoniazid on Mycobacterium bovis strain BCG. Infect Immun 3 (1971) 530-534
39. Jayaram R., Shandil R.K., Gaonkar S., Kaur P., Suresh B.L., Mahesh B.N., et al. Isoniazid pharmacokinetics-pharmacodynamics in an aerosol infection model of tuberculosis. Antimicrob Agents Chemother 48 (2004) 2951-2957
40. Wallis R.S., Patil S., Cheon S.H., Edmonds K., Phillips M., Perkins M.D., et al. Drug tolerance in Mycobacterium tuberculosis. Antimicrob Agents Chemother 43 (1999) 2600-2606
41. Mouton J.W., and Vinks A.A. Pharmacokinetic/pharmacodynamic modelling of antibacterials in vitro and in vivo using bacterial growth and kill kinetics: the minimum inhibitory concentration versus stationary concentration. Clin Pharmacokinet 44 (2005) 201-210